Antiandrogens in the Treatment of Prostate Cancer

This publication has 39 references indexed in Scilit:

• Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
  BJU International, 2006
• Risks and Benefits of Hormonal Manipulation as Monotherapy or Adjuvant Treatment in Localised Prostate Cancer
  European Urology, 2005
• Early Versus Delayed Androgen Deprivation for Prostate Cancer: New Fuel for an Old Debate
  Journal of Clinical Oncology, 2005
• Bicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme
  Prostate Cancer and Prostatic Diseases, 2005
• Comparative Effects of Bicalutamide (Casodex) versus Orchidectomy on Bone Mineral Density, Bone Remodelling, and Bone Biomechanics in Healthy Rats
  Urologia Internationalis, 2005
• Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial
  The Lancet Oncology, 2005
• Efficacy and Tolerability of Radiotherapy as Treatment for Bicalutamide-induced Gynaecomastia and Breast Pain in Prostate Cancer
  European Urology, 2005
• Prospective Randomized Trial Comparing Flutamide as Adjuvant Treatment versus Observation after Radical Prostatectomy for Locally Advanced, Lymph Node-Negative Prostate Cancer
  European Urology, 2004
• Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?
  Prostate Cancer and Prostatic Diseases, 2001
• Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer
  New England Journal of Medicine, 1999